Back to search results

Cardiotoxicity Assessment in Pediatric Cancer Survivors

This observational study is looking at how to better identify heart problems (cardiotoxicity) in young people who had cancer as children. Many childhood cancer survivors were treated with medicines like doxorubicin or daunorubicin, which can sometimes lead to heart failure later in life. Researchers will use heart imaging (cardiac MRI) and physical activity monitoring to find early signs of heart damage. The goal is to develop better ways to diagnose and treat these heart issues before they become serious. You may be able to join if you are 13-39 years old, had cancer before age 22, and were treated with anthracycline therapy at least two years ago. The study aims to enroll 150 participants.

Study design
This is an observational study, meaning researchers will monitor participants without providing new treatments. It plans to enroll 150 participants.
What's involved
Participants will undergo cardiac magnetic resonance imaging (MRI) and wear a hip-worn accelerometer to measure physical activity. Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main heart function measurement (Left ventricular ejection fraction) will be assessed at 3-5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04262830

Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure

Recruiting
Not specifiedAges 13–39Observational
Hari Narayan
~150 participants
Updated 2025-01-28 on ClinicalTrials.gov
What's tested:Cardiac magnetic resonance imaging (MRI)Accelerometer physical activity monitoring

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Left ventricular ejection fraction (LVEF)
Measured over 3 - 5 years

Conditions

Cardiotoxicity
Pediatric Cancer
Heart Failure

Explore related trials

CardiotoxicityChildhood Malignant Neoplasm

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Hari Narayan, MD · PRINCIPAL_INVESTIGATOR · University of California San Diego, Rady Children's Hospital

Who to contact

Hari Narayan, MD
[email protected]
8589665855 / 8589331718
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

English and Spanish speaking male and female subjects, ages 13-39 years old
Diagnosis of cancer at age \<22 years
Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior.

Exclusion

Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants.
Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia.
Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus).
Pregnancy (at the time of enrollment).

What this trial measures

  • Left ventricular ejection fraction (LVEF)3 - 5 years

    LVEF is an assessment of left ventricular global systolic function.